Portfolio Companies Make Headway in the US & Convergence Partners is Bound for Brazil & Southeast Asia

Hi Friends,? It has been an exciting summer of progress for our Germany & UK-based portfolio companies:

• neotiv, focusing on detection of cognitive impairment, was featured in Yahoo! Finance for their recent study results alongside Roche.
• neurocare group, specializing in precision TMS therapy, receives FDA clearance.
• Clerkenwell Health, leading in clinical trials utilizing psychedelic-assisted therapies, has a positive perspective on the FDA's recent decision on MDMA.

Find more about our portfolio companies, entry into Southeast Asia, and future opportunities below.

New Convergence SE Asia Hub

Three years ago, we established a cross-border acceleration platform to support European HealthTech startups in their China/ Hong Kong market entry and scale-up. Via a local expert network, our team is able to support all aspects of market access, from regulatory approval strategy, business development, local team setup to co-investor sourcing. Since then, Convergence Partners has served as a co-founder of Asia entities of leading EU healthcare innovators like @Abi Global Health, Sensit! and Cancerappy.

Through our new hub in Vietnam, we can support the market entry of EU startups in key markets like Vietnam, Thailand, Malaysia and Indonesia. Our current focus is on later stage digital health, medtech, and biopharma/ biotech companies. Please get in touch with our SE Asia lead, Pascal Joncour ([email protected]), if you are interested in accessing the fastest growing healthcare markets globally.

Portfolio Updates:

neotiv and Roche Reveal Study Results for Early Detection of Cognitive Impairment, Emphasizing Significant Market Potential

At the Alzheimer’s Association International Conference in Philadelphia, Roche and digital health company neotiv presented significant results from their study, re.cogni.ze, focusing on the digital early detection of mild cognitive impairment (MCI). The study highlighted the neotivCare app's effectiveness in MCI detection at various medical care levels. High user adherence (93%) and notable patient satisfaction, with 67.6% reporting added value, position the neotivCare app as a promising tool for early Alzheimer’s diagnosis. These findings are especially relevant in the U.S., where early-stage Alzheimer's medication has regulatory approval.

neurocare group Achieves FDA Clearance for Innovative iTBS Protocol

neurocare group is pleased to announce FDA clearance for its innovative intermittent Theta Burst Stimulation (iTBS) protocol, employed in the Apollo TMS Therapy System. This approval marks a significant advancement in non-invasive depression treatment, offering a time-efficient and flexible option with minimal side effects. This development not only enhances clinical outcomes but also expands neurocare’s market presence across over 175 clinics and institutions in the USA. The Apollo TMS Therapy System, now an established choice for major depression treatment resistant to traditional medications, is supported by most health insurance providers, paving the way for broad clinical adoption and growth potential for neurocare.

Clerkenwell Health Flips the Script on the FDA Rejection of MDMA Therapy

The FDA's recent rejection of MDMA-assisted therapy, while seemingly a setback, represents a pivotal moment for the psychedelic research sector, signaling a critical opportunity to refine research practices and elevate scientific standards. This decision underscores the rigorous demands of the drug approval process and the importance of robust methodologies and regulatory compliance. Clerkenwell Health, as a leading contract research organization (CRO), plays a vital role in advancing the field by optimizing trial designs and leveraging state-of-the-art technology to meet these heightened standards. This juncture is seen not only as a challenge but as a crucial call to action to make neuropsychiatric research more rigorous, patient-focused, and poised for future successes in transforming mental health care.

Connect With Us This Fall

We are speaking at the following events in October:?

• The REAL Summit in New York City, US (Oct. 17-18): Daniel Koppelkamm will be discussing VCs role in Mental Health innovation.?As a sponsor of the event, please enjoy a discounted Summit Pass with code REAL10.
• Horasis Global Meeting in Vitória, Brazil (Oct. 25-26): Pascal Joncour will be sharing insights cross-border scaling of Brain & Mental Health solutions.?

Discover Future Opportunities with Us

We invite accredited individuals to reach out for detailed information on two exciting opportunities that are on the horizon. For more about these potential ventures and how they align with your strategic goals, please contact us directly. Request Information Here.